 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2 March 1999 | Volume 130 Issue 5 | Pages 431-439
Purpose: To review clinical data on raloxifene hydrochloride, a selective estrogen receptor modulator that was recently approved for the prevention of osteoporosis in postmenopausal women.
Data Sources: English-language articles published from 1980 to May 1998 were identified through MEDLINE searches. Bibliographies, book chapters, and meeting abstracts were reviewed for additional relevant publications.
Study Selection: Publications that contained information on the background of development, structure, mechanism of action, tissue-selective effects, and adverse effects of raloxifene hydrochloride were included.
Data Extraction: Data in selected articles were reviewed, and relevant clinical information was extracted.
Data Synthesis: Raloxifene hydrochloride was developed in an effort to find a treatment for breast cancer and osteoporosis. It binds to the estrogen receptor and shows tissue-selective effects; thus, it belongs to a class of drugs recently described as selective estrogen receptor modulators. Tissue selectivity of raloxifene may be achieved through several mechanisms: the ligand structure, interaction of the ligand with different estrogen receptor subtypes in various tissues, and intracellular events after ligand binding. Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. An increase in bone mineral density at the spine, total hip, and total body has been reported with raloxifene but seems to be less than that seen with estrogen or alendronate therapy. Raloxifene has been shown to produce a reduction in total and low-density lipoprotein cholesterol concentrations similar to that produced by estrogen therapy, but high-density lipoprotein cholesterol and triglyceride concentrations do not increase during raloxifene therapy. In the uterus, raloxifene does not stimulate the endometrium. Long-term data on the effects of raloxifene in reduction of risk for fracture; prevention of cardiovascular events; cognitive function; and the incidence of breast, ovarian, and uterine cancer are not available. The most common adverse effect of raloxifene is hot flashes.
Conclusions: Raloxifene has been shown to have beneficial effects in selected organs in postmenopausal women. Although estrogen remains the drug of choice for hormonal therapy in most postmenopausal women, raloxifene may be an alternative in certain groups of women at risk for osteoporosis.
Author and Article Information
From University of California, San Francisco, and Veterans Affairs Medical Center, San Francisco, California.
Acknowledgments: The authors thank Dr. Steven T. Harris for critical reading of the manuscript.
Grant Support: In party by the Ananda Mahidol Foundation Scholarship, Thailand (Dr. Khovidhunkit), Department of Veterans Affairs Merit Review (Dr. Shoback), and National Institutes of Health grant DK 43400 (Dr. Shoback).
Requests for Reprints: Weerapan Khovidhunkit, MD, Metabolism Section, Veterans Affairs Medical Center, 4150 Clement Street, 111F, San Francisco, CA 94121.
Current Author Addresses: Dr. Khovidhunkit: Metabolism Section, Veterans Affairs Medical Center, 4150 Clement Street, 111F, San Francisco, CA 94121.
Dr. Shoback: Endocrine Section, Veterans Affairs Medical Center, 4150 Clement Street, 111N, San Francisco, CA 94121. CLINICAL REVIEW
Clinical Effects of Raloxifene Hydrochloride in Women
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  K. A. Johnson The SERM of My Dreams. J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3754 - 3756. [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Dunn, D. L. Wickerham, and L. G. Ford Prevention of Hormone-Related Cancers: Breast Cancer J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Palomba, T. Russo, F. Orio Jr, A. Sammartino, F. M. Sbano, C. Nappi, A. Colao, P. Mastrantonio, G. Lombardi, and F. Zullo Lipid, glucose and homocysteine metabolism in women treated with a GnRH agonist with or without raloxifene Hum. Reprod., February 1, 2004; 19(2): 415 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Palomba, T. Russo, F. Orio Jr, L. Tauchmanova, E. Zupi, P. L. B. Panici, C. Nappi, A. Colao, G. Lombardi, and F. Zullo Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial Hum. Reprod., December 1, 2002; 17(12): 3213 - 3219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Galbiati, P. L. Caruso, G. Amari, E. Armani, S. Ghirardi, M. Delcanale, and M. Civelli Pharmacological Actions of a Novel, Potent, Tissue-Selective Benzopyran Estrogen J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 196 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cranney, P. Tugwell, N. Zytaruk, V. Robinson, B. Weaver, J. Adachi, G. Wells, B. Shea, and G. Guyatt IV. Meta-Analysis of Raloxifene for the Prevention and Treatment of Postmenopausal Osteoporosis Endocr. Rev., August 1, 2002; 23(4): 524 - 528. [Full Text] [PDF]
|
|
|
|
|
|
S. Palomba, F. Orio Jr., M. Morelli, T. Russo, M. Pellicano, E. Zupi, G. Lombardi, C. Nappi, P. L. B. Panici, and F. Zullo Raloxifene Administration in Premenopausal Women with Uterine Leiomyomas: A Pilot Study J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3603 - 3608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition J. Clin. Oncol., August 1, 2002; 20(15): 3328 - 3343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Greenberger, T. Annable, K. I. Collins, B. S. Komm, C. R. Lyttle, C. P. Miller, P. G. Satyaswaroop, Y. Zhang, and P. Frost A New Antiestrogen, 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), Inhibits the Growth of Tamoxifen-sensitive and -resistant Tumors and Is Devoid of Uterotropic Effects in Mice and Rats Clin. Cancer Res., October 1, 2001; 7(10): 3166 - 3177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Chapurlat, S. K. Ewing, D. C. Bauer, and S. R. Cummings Influence of Smoking on the Antiosteoporotic Efficacy of Raloxifene J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4178 - 4182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Compston Sex Steroids and Bone Physiol Rev, January 1, 2001; 81(1): 419 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Neugarten, A. Acharya, J. Lei, and S. Silbiger Selective estrogen receptor modulators suppress mesangial cell collagen synthesis Am J Physiol Renal Physiol, August 1, 2000; 279(2): F309 - F318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Chlebowski Reducing the Risk of Breast Cancer N. Engl. J. Med., July 20, 2000; 343(3): 191 - 198. [Full Text] [PDF]
|
|
|
|
|
|
K. M. Prestwood, M. Gunness, D. B. Muchmore, Y. Lu, M. Wong, and L. G. Raisz A Comparison of the Effects of Raloxifene and Estrogen on Bone in Postmenopausal Women J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2197 - 2202. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Schrag, K. M. Kuntz, J. E. Garber, and J. C. Weeks Life Expectancy Gains From Cancer Prevention Strategies for Women With Breast Cancer and BRCA1 or BRCA2 Mutations JAMA, February 2, 2000; 283(5): 617 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. An, R. C. J. Ribeiro, P. Webb, J.-A. Gustafsson, P. J. Kushner, J. D. Baxter, and D. C. Leitman Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators PNAS, December 21, 1999; 96(26): 15161 - 15166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. McNagny Prescribing Hormone Replacement Therapy for Menopausal Symptoms Ann Intern Med, October 19, 1999; 131(8): 605 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Perry III The Endocrinology of Aging Clin. Chem., August 1, 1999; 45(8): 1369 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Franks and K. K. Steinberg Encouraging News From the SERM Frontier JAMA, June 16, 1999; 281(23): 2243 - 2244. [Full Text] [PDF]
|
|
|
|
|
|
R. T. Chlebowski, D. E. Collyar, M. R. Somerfield, and D. G. Pfister American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene J. Clin. Oncol., June 1, 1999; 17(6): 1939 - 1939. [Abstract] [Full Text] [PDF]
|
|
